Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cryo-Cell InternationalCCEL +3.93%58 Cash Ratio is 0.20 as of May. 2026, which is 38% below its 10-year median of 0.32. GuruFocus rates CCEL with a GF Score™ of 58/100 and a GF Value™ of $5.45 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 662 Healthcare Providers & Services companies, Cryo-Cell International ranks worse than 78.4% on this metric.
Cryo-Cell International has a Cash Ratio of 0.20. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Cryo-Cell International's Cash Ratio or its related term are showing as below:
CCEL'
s Cash Ratio Range Over the Past 10 Years
Min: 0.05 Med: 0.32 Max: 0.64
Current: 0.2
During the past 13 years, Cryo-Cell International's highest Cash Ratio was 0.64. The lowest was 0.05. And the median was 0.32.
CCEL's Cash Ratio is ranked worse than 78.4% of 662
companies
in the Healthcare Providers & Services industry
Industry Median: 0.58
vs CCEL: 0.20
Cryo-Cell International (AMEX:CCEL) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Cryo-Cell International Cash Ratio Related Terms
Cryo-Cell International Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Cryo-Cell International's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International Cash Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (CCEL) has a Cash Ratio of 0.20 as of May. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cryo-Cell International and its competitors. This is 38% below median its historical median of 0.32. Over the past decade, Cryo-Cell International's Cash Ratio has ranged from 0.05 to 0.64. According to the industry distribution chart, Cryo-Cell International ranks #519 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 78.4%.
Is Cryo-Cell International's Cash Ratio too high?
Cryo-Cell International's current Cash Ratio of 0.20 is 38% below median its 10-year median of 0.32. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.64. The Healthcare Providers & Services industry median Cash Ratio is 0.58. Cryo-Cell International's value of 0.20 is 65.5% below this industry median. Based on the distribution chart, Cryo-Cell International ranks #519 out of 662 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Cash Ratio compare to EHSI and PIII?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #519 out of 662 companies for Cash Ratio. This places Cryo-Cell International in the lower half of its industry. The industry median Cash Ratio is 0.58. Cryo-Cell International's value of 0.20 is 65.5% below this benchmark. Historically, Cryo-Cell International's own Cash Ratio has ranged from 0.05 to 0.64 over the past decade. While the company's 10-year median is 0.32 vs. the industry median of 0.58, Cryo-Cell International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Healthcare Providers & Services company?
The median Cash Ratio among Healthcare Providers & Services companies is 0.58, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current Cash Ratio of 0.20 is 65.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median Cash Ratio is 0.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current Cash Ratio is 0.20, which is 38% below median its own 10-year median of 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (CCEL) is currently considered Possible Value Trap. The stock's GF Value™ is $5.45, compared to a current price of $3.70 — trading 32.1% below its estimated fair value. The current Cash Ratio is 0.20, which is 38% below median its 10-year median of 0.32 and 65.5% below the Healthcare Providers & Services industry median of 0.58. Cryo-Cell International's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Cryo-Cell International (CCEL), the current Cash Ratio is 0.20 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (CCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of $3.70 is trading 32.1% below its estimated GF Value™ of $5.45.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for CCEL:
Cash Ratio: 0.20 (38% below median its 10-year median of 0.32)
GF Value™: $5.45 vs. price of $3.70 (32.1% below fair value)
Industry Position: 65.5% below the Healthcare Providers & Services median (#519 of 662)
No single metric tells the full story. See the CCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for CCEL
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CCEL has been successfully added to your 
